Group Leader Statistics, Principal Scientist II
Tim joined Metrum in 2019, bringing 12 years of experience in the pharmaceutical industry. He attained his Ph.D. in Statistics from the University of Queensland, where he applied optimal design methods to PK/PD models. He then worked at Eli Lilly and Company in the PK/PD & Pharmacometrics department, using modeling and simulation to inform decision making in all phases of drug development across a range of therapeutic areas.
October 16, 2026
Yuchen Wang¹, Matthew Wiens², Ke Szeto¹, Timothy Waterhouse², Vivek Purohit¹, Leandro L. Santos³, Jessica Wojciechowski¹
¹Clinical and Quantitative Pharmacology, Incyte Corporation, Wilmington, DE, USA; ²Metrum Research Group, Boston, MA, USA; ³Clinical Development, Incyte Corporation, Wilmington, DE, USA
Presented at the 2026 American Conference on Pharmacometrics (ACoP 2026), an International Conference on Pharmacometrics in the US (ICoP – US), on October 14th, 2026.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent nodules, abscesses, and draining tunnels (dTs) that contribute substantially to disease burden. The presence of dTs is indicative of irreversible tissue damage, and a surrogate marker of a more challenging to treat HS, making dT count (dTC) a clinically meaningful endpoint. Povorcitinib is an oral, highly selective Janus kinase 1 inhibitor with demonstrated efficacy in reducing dTC in the phase 3 STOP-HS1 and –HS2 studies. Because dTC changes dynamically over time, a continuous-time Markov model (birth-death process) was developed to characterize the longitudinal relationship between povorcitinib exposure and dTC in patients with moderate to severe HS.
October 9, 2026
Marc R. Gastonguay, William Knebel, Timothy Waterhouse, Jeannine Fisher, Brian Corrigan
Presented at the 2026 American Conference on Pharmacometrics (ACoP 2026), an International Conference on Pharmacometrics in the US (ICoP – US), on October 12th, 2026.
Regulatory submissions for new drugs (NDAs/BLAs) increasingly rely on MIDD (model-informed drug development) analyses to support dosing, labeling, and design of post-approval trial commitments. Frequently, MIDD related activities (data cleaning/prep, analysis, summary document preparation) are on the filing critical path (CP) following completion of the final registration studies, with delays directly impacting time to file. These delays impact overall medicine value and access for patients. This case study highlights a MIDD acceleration (MIDD-A) strategy that resulted in a meaningful reduction in the NDA submission critical path (CP) for an ongoing Phase 3 drug development program.
June 17, 2025
This work illustrates how integrated population PK modeling of antibody-conjugated payload and free payload analytes for an ADC can inform development strategies for targeted therapies—particularly in complex oncology settings.